UCLA researchers in the Departments of Medicine and Cardiology have identified a novel gene and pathway in the regulation of insulin sensitivity and discovered an inhibitor of this gene useful for treating AGPAT5-related diseases.
Insulin resistance (IR), a condition in which the body’s cells fail to respond to insulin, is a significant worldwide health problem and leads to diseases such as Type-II diabetes, coronary artery disease, and fatty liver disease. The identification of efficacious therapies to improve insulin sensitivity is essential to the treatment of these metabolic diseases and conditions. However, the genetic factors that control and the variation of genetic factors that contribute to IR have not been well studied.
UCLA researchers have identified a genetic variant, AGPAT isoform 5 (AGPAT5), that contributes to the development of insulin resistance in mouse models. Furthermore, they have developed an inhibitor and methodology for reducing expression of AGPAT5 mRNA and protein in vivo, allowing for the regulation of insulin and insulin sensitivity.
|United States Of America||Issued Patent||10,364,433||07/30/2019||2014-730|
diabetes, metabolic diseases, genetic diseases, insulin resistance, cardiometabolic disease, coronary artery disease, cardiovascular, obesity, metabolic syndrome